GlassScriptPhysician profile
Christopher M Mccourt
NPI 1376994475
$6,460.52
in general payments reported to CMS, 2019-2025
23 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,008 · 2022: $924 · 2023: $845 · 2024: $1,939 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.72 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.60 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $980.34 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $695.87 | 2021-2025 | Caplyta |
| Lundbeck LLC | $639.44 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $418.68 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $356.98 | 2022-2025 | Auvelity |
| Alkermes, INC. | $343.47 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $268.20 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $210.93 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $205.57 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $204.33 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $201.58 | 2022-2025 | Trintellix, Vyvanse |
| Teva Pharmaceuticals USA, INC. | $138.95 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $114.46 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $111.67 | 2023-2024 | Azstarys, Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $99.23 | 2024-2025 | Zurzuvae |
| Tris Pharma INC | $99.12 | 2024-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $76.74 | 2024-2025 | Aplenzin |
| Noven Therapeutics, LLC | $46.24 | 2021-2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $42.52 | 2024 | |
| Almatica Pharma LLC | $19.62 | 2024 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.83 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.15 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mccourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.